ClinicalTrials.gg
RecruitingNCT04040920Updated May 16, 2025

Ozone Application Before Fissure Sealants

An interventional study of Ozone and Pits and fissure sealants in Caries,Dental, sponsored by IRCCS Burlo Garofolo. Recruiting at 1 site in Italy. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by IRCCS Burlo Garofolo · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
6 Years to 16 Years
Sex
All
01

Study summary

Decay is a multifactorial infective degenerative disease of hard dental tissues, caused by Streptococcus mutans and Lactobacillus forming the bacterial biofilm of teeth surfaces. Decays generally evolve in fissures and pits of secondary molars. Pits and fissure sealants prevent decays if performed in two years from eruption. Ozone has bactericidal effect and remineralizing capacity on enamel.

The aim of this study is to assess the effectiveness of ozone application before sealants in increasing their duration in time.

02

Conditions studied

  • Caries,Dental

Browse trials for

Keywords

  • Ozone
  • Pits and fissures sealants
  • Prevention
03

In context

Dental Caries

1,171 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

This study's planned enrollment of 67 is above the median of 60 across 967 interventional studies indexed under Dental Caries.

Browse Dental Caries studies →

Lead sponsor

IRCCS Burlo Garofolo is the lead sponsor of 89 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • first or second secondary molars to be sealed
  • possibility to isolate with rubber dam both the teeth involved
  • no clear signs of pigmentations
  • good general health

Exclusion criteria

Exclusion Criteria:

  • latex allergy
  • epilepsy or other severe neurological pathologies
  • psychiatric disease
  • excessive sensibility to electrical current
  • severe asthma
  • enamel disorders, such as amelogenesis imperfect, white spots, fluorosis or Molar Incisors Hypomineralization
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    Ozone therapy

    Ozone application before pits and fissure sealants

    Device: Ozone · Other: Pits and fissure sealants

  • Active comparator
    Pits and fissure sealants

    Other: Pits and fissure sealants

Interventions

  • DeviceOzone

    One minute of pretreatment with ozone by using the OzoneDTA device

  • OtherPits and fissure sealants

    cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';

06

What researchers measure

Primary outcomes

  1. Sealants failure

    Frequency of sealed failure defined as presence of to one or more of these outcomes: Marginal fissure; Sealant fracture; Decay; Marginal pigmentations; Sealant detachment Evaluation of the relative frequency of the different causes of failure

    Time frame: 12 months after sealant

Secondary outcomes

  1. Sealants failure

    Frequency of sealed failure defined as presence of to one or more of these outcomes: Marginal fissure; Sealant fracture; Decay; Marginal pigmentations; Sealant detachment Evaluation of the relative frequency of the different causes of failure

    Time frame: 6 months after sealant

  2. Sealants failure

    Frequency of sealed failure defined as presence of to one or more of these outcomes: Marginal fissure; Sealant fracture; Decay; Marginal pigmentations; Sealant detachment Evaluation of the relative frequency of the different causes of failure

    Time frame: 24 months after sealant

  3. Secondary decay in failed sealants

    Frequency of secondary decay in teeth with failed sealants

    Time frame: 6 months after sealant

  4. Secondary decay in failed sealants

    Frequency of secondary decay in teeth with failed sealants

    Time frame: 12 months after sealant

  5. Secondary decay in failed sealants

    Frequency of secondary decay in teeth with failed sealants

    Time frame: 24 months after sealant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data collected during the study will be available from the Study Director on reasonable request after evaluation of a protocol approved by an Ethical Committee

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After publication of data on peer reviewed journals

Access criteria: Data collected during the study will be available from the Study Director on reasonable request after evaluation of a protocol approved by an Ethical Committee

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04040920
Lead sponsor
IRCCS Burlo Garofolo
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Jun 17, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 16, 2025

Study contacts

Milena Cadenaro, DDS,MSc,PhD
Contact
milena.cadenaro@burlo.trieste.it
+390403785358
Chiara Navarra, DDS,MSc,PhD
Contact
chiara.navarra@burlo.trieste.it
+390403785358
Milena Cadenaro, DDS,MSc,PhD
study chair · IRCCS Burlo Garofolo
Maddalena Chermetz, DDS,MSc
principal investigator · IRCCS Burlo Garofolo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion